@文章{信息:doi/10.2196/15699，作者=“Rodriguez Hermosa, Juan Luis和Fuster Gomila, Antonia和Puente Maestu, Luis和Amado Diago, Carlos Antonio和Callejas Gonz{\'a}lez, Francisco Javier和Malo De Molina Ruiz, Rosa和Fuentes Ferrer, Manuel E和{\'a} lvarez Sala-Walther, Jose Luis和Calle Rubio, Myriam”，标题=“慢性阻塞性肺疾病患者急性加重检测智能手机应用程序的依从性和有效性:队列研究”，期刊=“JMIR Mhealth Uhealth”，年=“2020”，月=“Mar”，日=“19”，卷=“8”，数=“3”，页=“e15699”，关键词=“慢性阻塞性肺疾病;移动健康;合规;，摘要=“背景:近年来，移动健康(mHealth)相关的应用程序已经开发出来，以帮助管理慢性疾病。应用程序可以让患有慢性阻塞性肺疾病(COPD)等以病情恶化为特征的慢性疾病的患者追踪甚至怀疑疾病的恶化，从而促进自我管理和及时干预。然而，没有足够的证据表明患者在日常使用移动健康应用程序进行慢性疾病监测方面的依从性。目的:本研究旨在提供进一步的证据，支持通过智能手机应用程序Prevexair前瞻性地记录日常症状，作为检测COPD恶化的有用策略。它还旨在分析使用Prevexair记录的日常依从性和慢性阻塞性肺病急性加重的频率和特征。方法:这是一项多中心队列研究，前瞻性病例招募包括116例COPD患者，这些患者有频繁加重的病史，并在6个月的时间内进行监测。 At recruitment, the Prevexair app was installed on their smartphones, and patients were instructed on how to use the app. The information recorded in the app included symptom changes, use of medication, and use of health care resources. The patients received messages on healthy lifestyle behaviors and a record of their cumulative symptoms in the app. There was no regular contact with the research team and no mentoring process. An exacerbation was considered reported if medical attention was sought and considered unreported if it was not reported to a health care professional. Results: Overall, compliance with daily records in the app was 66.6{\%} (120/180), with a duration compliance of 78.8{\%}, which was similar across disease severity, age, and comorbidity variables. However, patients who were active smokers, with greater dyspnea and a diagnosis of depression and obesity had lower compliance (P<.05). During the study, the patients experienced a total of 262 exacerbations according to daily records in the app, 99 (37.8{\%}) of which were reported exacerbations and 163 (62.2{\%}) were unreported exacerbations. None of the subject-related variables were found to be significantly associated with reporting. The duration of the event and number of symptoms present during the first day were strongly associated with reporting. Despite substantial variations in the COPD Assessment Test (CAT), there was improvement only among patients with no exacerbation and those with reported exacerbations. Nevertheless, CAT scores deteriorated among patients with unreported exacerbations. Conclusions: The daily use of the Prevexair app is feasible and acceptable for patients with COPD who are motivated in their self-care because of frequent exacerbations of their disease. Monitoring through the Prevexair app showed great potential for the implementation of self-care plans and offered a better diagnosis of their chronic condition. ", issn="2291-5222", doi="10.2196/15699", url="http://mhealth.www.mybigtv.com/2020/3/e15699/", url="https://doi.org/10.2196/15699", url="http://www.ncbi.nlm.nih.gov/pubmed/32191213" }